Price History

Hover for the daily close. The dotted line marks the period open.

Compare RXST with… →

RXST Key Statistics

As of Sep 4, 2026

Trading

Open: $6.47
Previous Close: $6.54
Day's Range: 6.34–6.63
52-Week Range: 4.48–13.22
Volume: 560.30K
Beta: 1.16

Valuation

Market Cap: $265.16M
P/E Ratio: unprofitable
P/S ratio: 2.08
EPS (ttm): −1.14

Financials (FY)

Revenue (FY): $134.48M−3.89%
Net Income (FY): −$38.94M
Profit margin: −36.80%
Shares Outstanding: 41.59M
1-Year Return: −24.73%

Dividend and dates

Earnings Date: November 4, 2026estimated
Avg Volume: 1.13M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RXST Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−29.69%+12.62%+218.23%−14.73%−69.69%−38.82%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−38.82%
2025	−69.69%
2024	−14.73%
2023	+218.23%
2022	+12.62%
2021 (partial year)	−29.69%

As of September 4, 2026.

RXST Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$134.48M	−$38.94M	−29.0%
2024	$139.93M	−$27.46M	−19.6%
2023	$89.08M	−$48.61M	−54.6%
2022	$49.01M	−$66.76M	−136.2%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$134.48M	$103.01M	−$48.19M	−$38.94M	−29.0%
2024	$139.93M	$98.94M	−$36.86M	−$27.46M	−19.6%
2023	$89.08M	$53.77M	−$50.09M	−$48.61M	−54.6%
2022	$49.01M	$21.33M	−$63.32M	−$66.76M	−136.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RXST Valuation vs Medical Devices Median

Median of 151 stocks

Metric	RXST	Medical Devices median	vs median
P/S ratio	2.08	2.98	30% below
Profit margin	−36.80%	−1.69%	35.1 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

RxSight, Inc. (RXST) is capitalised at $265.16M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 461.

The 52-week range on file runs from $4.48 to $13.22. RXST last closed at $6.38 on September 4, 2026. That is −$0.17 (−2.52%) against the previous close. The latest close sits 42.3% above that 52-week low.

Financial Health

In fiscal 2025, RxSight, Inc. reported revenue of $134.48M. Against the prior fiscal year total of $139.93M, that is a change of −3.89%. The same year closed with a net loss of $38.94M. The reported profit margin is −36.8%. That is 35.1 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −1.14.

Across the 4 fiscal years on file, revenue moves from $49.01M in 2022 to $134.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.08. On price-to-sales that is 30.17% below the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.16. Daily returns over the trailing 5 years annualize to a volatility of 67.25%. The trailing one-year price return is −24.73%. Across 5 years the annualized return works out at −16.84%.

Growth & Income

No dividend is on file for RXST.

Across the complete calendar years on file, 2023 returned +218.23% and 2025 returned −69.69%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −38.82% year to date.

Peer Comparison

RxSight, Inc. (RXST) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
RxSight, Inc.	RXST	$265.16M	—
Abbott Laboratories	ABT	$187.45B	35.1
Medtronic plc.	MDT	$120.46B	22.9
Stryker Corporation	SYK	$116.27B	31.9

The Medical Devices industry average P/E ratio is 26.8x. RxSight, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

MDT

Medtronic plc.

$120.46B

SYK

Stryker Corporation

$116.27B

BSX

Boston Scientific Corporation

$69.27B

EW

Edwards Lifesciences Corporation

$51.82B

DXCM

DexCom, Inc.

$33.17B

View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About RxSight, Inc.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Visit website →

RxSight, Inc. (RXST) Stock Analysis